Skip to content

Abstract 15142: Unraveling the Gene Architecture of the Sub-Diagnostic HCM 'Gray-Zone'

Nov 2026 · Circulation · 0 citations

Abstract

Background: Hypertrophic Cardiomyopathy (HCM) is diagnosed by unexplained left ventricular hypertrophy (LVH) ≥15mm. This threshold is unadjusted for age and sex, contributing to diagnostic uncertainty for unexplained hypertrophy in the sub-diagnostic ‘gray-zone’ (≥12 to <15 mm). We characterized the genetic architecture of gray-zone LVH and compared clinical features and outcomes between carriers and non-carriers of rare variants in HCM-associated or HCM-genocopy genes. Methods: The Royal Brompton (RBH) Biobank prospectively enrolled 6,548 patients referred for diagnostic Cardiac Magnetic Resonance (CMR) imaging. Subjects with gray-zone LV maximum wall thickness (LVMWT ≥12 <15mm) were included, excluding those aged <16 years, with >mild aortic stenosis, a confirmed HCM phenocopy (e.g. infiltrative or syndromic LVH), a known family history of HCM, or isolated apical hypertrophy (where alternative criteria apply). Patients underwent genetic sequencing, and were assessed for rare (protein altering, allele frequency < 1 in 1000) variants in 28 genes with strong/definitive evidence for HCM or other genetic causes of LVH. Results: In total, 270 patients with gray-zone LVH were identified (mean age 58.3±13.9 years; male 79.6%; European ancestry 83.7%; LVMWT 12.9±0.8mm; hypertensive 53.0%; diabetic 13.3%), of whom 230 underwent genetic analysis. Over a median follow-up of 11.37 years [IQR 10.19-12.73] there were 44 deaths. Patients were most commonly referred for evaluation of possible cardiomyopathy (n=133, 57.8%), ischemia (n=32, 13.9%) or ventricular dysfunction (n=28, 12.2%). A rare variant (allele frequency <1 in 1000) in an HCM/LVH-associated gene was present in 18.3% (n=42), but only 2.6% carried a variant reported as pathogenic/likely pathogenic (P/LP) in ClinVar (n=6: MYBPC3=2, TTR=2, MYH7=1, TNNI3=1). Carriers and non-carriers did not differ in age, sex, hypertension history or CMR features (LVMWT, LVEF, LV volumes, late gadolinium enhancement); diabetes was less common in carriers (2.4% vs 16%, P=0.02). Rare-variant carriage did not predict all-cause mortality (HR 1.03, 95% CI 0.46-2.32) after adjustment for age and sex. In a subset without hypertension (n=109/230), 5 (4.6%) carried a P/LP variant. A personalized LVH threshold (adjusted for age, sex and body surface area) reclassified 27 (24.8%) as having demographically-adjusted LVH but did not improve P/LP yield (3.7%, n=1). Conclusion: In this referral cohort with ‘gray-zone’ LVH (≥12 to <15mm), rare-variant carriage was relatively common (18.3%) but confirmed P/LP variants were uncommon (2.6%), and carriage did not predict all-cause mortality. Demographically-adjusted LVH thresholds did not materially improve genetic yield, suggesting that escalation of genetic testing or diagnostic re-labeling in gray-zone LVH should not rely on wall thickness alone but be guided by other associated risk factors.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.